Bristol Myers Squibb (BMY) Debt Ratio (2009 - 2026)
Bristol Myers Squibb (BMY) reported Debt Ratio of 0.51 for Q1 2026, down 4.41% year-over-year from 0.54 in Q1 2025, and up 2.62% on a QoQ basis from 0.5 in Q4 2025.
Bristol Myers Squibb (BMY) has 18 years of Debt Ratio data on file, last reported at 0.51 in Q1 2026.
- Quarterly Debt Ratio fell 4.41% year-over-year to 0.51 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 0.51 (down 4.41% YoY) and the FY2025 annual result came in at 0.5, down 6.55% from the prior year.
- Debt Ratio advanced to 0.51 in Q1 2026 per BMY's latest filing, from 0.5 in the prior quarter.
- Across five years, Debt Ratio topped out at 0.56 in Q1 2024 and bottomed at 0.4 in Q3 2022.
- The 5-year median for Debt Ratio is 0.5 (2025), against an average of 0.47.
- The widest annual swing landed in 2023, when Debt Ratio slipped 8.07%; it then jumped 40.12% in 2024.
- Tracing BMY's Debt Ratio over 5 years: stood at 0.41 in 2022, then climbed by 2.92% to 0.42 in 2023, then increased by 28.28% to 0.54 in 2024, then decreased by 6.55% to 0.5 in 2025, then gained by 2.62% to 0.51 in 2026.
- Per Business Quant, the three latest BMY Debt Ratio figures stand at 0.51 (Q1 2026), 0.5 (Q4 2025), and 0.51 (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Debt Ratio (Qtr) |
|---|---|---|---|---|---|
| 1 | Novartis Ag | 107,124,802.25 Bn | 107,124,802.25 Bn | - | - |
| 2 | Eli Lilly | 969.00 Bn | 963.72 Bn | 16.22 Bn | 0.37 |
| 3 | Johnson & Johnson | 539.46 Bn | 517.41 Bn | 15.96 Bn | 0.27 |
| 4 | AbbVie | 376.92 Bn | 367.57 Bn | 10.78 Bn | 0.47 |
| 5 | Merck | 285.00 Bn | 279.35 Bn | 12.09 Bn | 0.38 |
| 6 | Amgen | 177.58 Bn | 165.55 Bn | 5.87 Bn | 0.62 |
| 7 | Gilead Sciences | 163.22 Bn | 155.50 Bn | 5.52 Bn | 0.39 |
| 8 | Pfizer | 145.86 Bn | 133.09 Bn | -1.21 Bn | 0.31 |
| 9 | Bristol Myers Squibb | 111.90 Bn | 101.44 Bn | 8.07 Bn | 0.51 |
| 10 | Gsk | 88.34 Bn | 83.66 Bn | - | 0.29 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 0.51 |
| Dec 31, 2025 | 0.50 |
| Sep 30, 2025 | 0.51 |
| Jun 30, 2025 | 0.52 |
| Mar 31, 2025 | 0.54 |
| Dec 31, 2024 | 0.54 |
| Sep 30, 2024 | 0.53 |
| Jun 30, 2024 | 0.55 |
| Mar 31, 2024 | 0.56 |
| Dec 31, 2023 | 0.42 |
| Sep 30, 2023 | 0.41 |
| Jun 30, 2023 | 0.40 |
| Mar 31, 2023 | 0.40 |
| Dec 31, 2022 | 0.41 |
| Sep 30, 2022 | 0.40 |
| Jun 30, 2022 | 0.42 |
| Mar 31, 2022 | 0.44 |
| Dec 31, 2021 | 0.41 |
| Sep 30, 2021 | 0.40 |
| Jun 30, 2021 | 0.41 |
| Mar 31, 2021 | 0.41 |
| Dec 31, 2020 | 0.43 |
| Sep 30, 2020 | 0.36 |
| Jun 30, 2020 | 0.36 |
| Mar 31, 2020 | 0.36 |
| Dec 31, 2019 | 0.36 |
| Sep 30, 2019 | 0.43 |
| Jun 30, 2019 | 0.45 |
| Mar 31, 2019 | 0.17 |
| Dec 31, 2018 | 0.21 |
| Sep 30, 2018 | 0.22 |
| Jun 30, 2018 | 0.23 |
| Mar 31, 2018 | 0.23 |
| Dec 31, 2017 | 0.24 |
| Sep 30, 2017 | 0.25 |
| Jun 30, 2017 | 0.25 |
| Mar 31, 2017 | 0.26 |
| Dec 31, 2016 | 0.20 |
| Sep 30, 2016 | 0.20 |
| Jun 30, 2016 | 0.21 |
| Mar 31, 2016 | 0.21 |
| Dec 31, 2015 | 0.21 |
| Sep 30, 2015 | 0.23 |
| Jun 30, 2015 | 0.23 |
| Mar 31, 2015 | 0.22 |
| Dec 31, 2014 | 0.23 |
| Sep 30, 2014 | 0.23 |
| Jun 30, 2014 | 0.23 |
| Mar 31, 2014 | 0.23 |
| Dec 31, 2013 | 0.22 |
| Sep 30, 2013 | 0.20 |
| Jun 30, 2013 | 0.20 |
| Mar 31, 2013 | 0.22 |
| Dec 31, 2012 | 0.21 |
| Sep 30, 2012 | 0.20 |
| Jun 30, 2012 | 0.17 |
| Mar 31, 2012 | 0.17 |
| Dec 31, 2011 | 0.17 |
| Sep 30, 2011 | 0.18 |
| Jun 30, 2011 | 0.17 |
| Mar 31, 2011 | 0.18 |
| Dec 31, 2010 | 0.18 |
| Dec 31, 2009 | 0.21 |
| Sep 30, 2009 | 0.21 |
| Jun 30, 2009 | 0.21 |